Amid intensifying competition in the weight-loss drug market, Novo Nordisk's (NVO) early January release of its oral GLP-1 version sparked hope for a...
Novo Nordisk (NVO), the Danish pharmaceutical leader, has reclaimed its dominance in the GLP-1 market, driven by strategic agility and innovative...
In the pharmaceutical space, there’s nothing hotter than weight-loss drugs. Seemingly every YouTube video features an advertisement on how...
Novo Nordisk (NVO) has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly (LLY) plateaued but...
Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE:NVO). It’s quite possible that...
Hims & Hers Health (HIMS) stock saw it’s shares drop more than 30% during trading on Monday. The sharp decline was one of the steepest...
Shares of Hims & Hers Health (HIMS) are getting crushed today after the Food & Drug Administration determined there is no longer a shortage...
Next to artificial intelligence, one of the biggest investment themes over the past few years has been a class of anti-obesity drugs called...
Shares of Eli Lilly (LLY) and other pharmaceutical companies dropped significantly on Friday. The selloff was triggered by the announcement that...
Novo Nordisk (NVO) stock dropped more than 15% on Friday following an update on its obesity drug that fell short of expectations. Headlines from the...